Prelude Therapeutics (PRLD) News Today → Does this chart look familiar? (From InvestorPlace) (Ad) Free PRLD Stock Alerts $3.80 +0.07 (+1.88%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 2:10 AM | americanbankingnews.comPrelude Therapeutics (NASDAQ:PRLD) Stock Price Up 1.9%May 11 at 7:29 PM | msn.comPrelude Therapeutics to Showcase at Citizens JMP Life Sciences ConferenceMay 10, 2024 | msn.comPrelude Therapeutics Progresses in Cutting-Edge Cancer Treatment DevelopmentMay 9, 2024 | globenewswire.comPrelude Therapeutics to Participate in Citizens JMP Life Sciences ConferenceMay 8, 2024 | finanznachrichten.dePrelude Therapeutics, Inc.: Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prelude Therapeutics on Strong Financials and Promising Clinical ProspectsMay 7, 2024 | investorplace.comPRLD Stock Earnings: Prelude Therapeutics Beats EPS for Q1 2024May 7, 2024 | globenewswire.comPrelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 13, 2024 | finance.yahoo.comSeveral Insiders Invested In Prelude Therapeutics Flagging Positive NewsApril 9, 2024 | globenewswire.comPrelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingMarch 30, 2024 | morningstar.comPrelude Therapeutics Inc Ordinary Shares PRLDMarch 16, 2024 | finance.yahoo.comPRLD Apr 2024 5.000 callMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD) and Prelude Therapeutics (PRLD)March 13, 2024 | marketbeat.comPrelude Therapeutics (NASDAQ:PRLD) Research Coverage Started at JMP SecuritiesJMP Securities assumed coverage on Prelude Therapeutics in a research report on Wednesday. They set an "outperform" rating and a $7.00 price objective on the stock.March 6, 2024 | marketbeat.comFmr LLC Lowers Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD)Fmr LLC cut its holdings in shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD - Free Report) by 13.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,131,433 shares of the company's stock after selling 808March 5, 2024 | globenewswire.comPrelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual MeetingFebruary 29, 2024 | globenewswire.comPrelude Therapeutics to Participate in Barclays Global Healthcare ConferenceFebruary 20, 2024 | marketbeat.comPrelude Therapeutics (NASDAQ:PRLD) Rating Lowered to Neutral at HC WainwrightHC Wainwright lowered Prelude Therapeutics from a "buy" rating to a "neutral" rating and set a $5.00 price target on the stock. in a research note on Tuesday.February 17, 2024 | finance.yahoo.comHere's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn SituationFebruary 17, 2024 | msn.comNew Accounting & Financial Operations Risk for Prelude Therapeutics, Inc. – What’s the Latest?February 16, 2024 | marketbeat.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Sees Significant Growth in Short InterestPrelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 522,000 shares, an increase of 15.6% from the January 15th total of 451,500 shares. Currently, 1.8% of the shares of the stock are sold short. Based on an average daily volume of 141,000 shares, the days-to-cover ratio is presently 3.7 days.February 16, 2024 | msn.comPrelude Therapeutics files to sell 7.94M shares for holdersFebruary 16, 2024 | markets.businessinsider.comPrelude Therapeutics Incorporated Registered ShsFebruary 15, 2024 | finance.yahoo.comPrelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024February 15, 2024 | globenewswire.comPrelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024February 15, 2024 | marketbeat.comPrelude Therapeutics (NASDAQ:PRLD) Trading Up 8.3%Prelude Therapeutics (NASDAQ:PRLD) Shares Up 8.3%February 5, 2024 | seekingalpha.comPrelude Therapeutics: Interesting Pipeline That Is Too Early To Warrant My BuyJanuary 14, 2024 | marketbeat.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Down 34.3% in DecemberPrelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) saw a large decline in short interest in December. As of December 31st, there was short interest totalling 446,900 shares, a decline of 34.3% from the December 15th total of 680,100 shares. Based on an average daily trading volume, of 208,500 shares, the short-interest ratio is presently 2.1 days. Approximately 1.5% of the shares of the stock are sold short.January 14, 2024 | finance.yahoo.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) is definitely on the radar of hedge funds investors who own 33% of the companyDecember 19, 2023 | msn.comMorgan Stanley Downgrades Prelude Therapeutics (PRLD)December 19, 2023 | markets.businessinsider.comMorgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To KnowDecember 18, 2023 | nasdaq.comPrelude Therapeutics Incorporated Common Stock (PRLD)December 11, 2023 | finance.yahoo.comPrelude Therapeutics Announces $25 Million Private PlacementNovember 20, 2023 | benzinga.comPrelude Therapeutics Stock (NASDAQ:PRLD) Dividends: History, Yield and DatesNovember 5, 2023 | finance.yahoo.comPrelude Therapeutics Insiders Are Down US$149k But Regain Some LossesNovember 3, 2023 | finance.yahoo.comQ3 2023 Abcellera Biologics Inc Earnings CallNovember 1, 2023 | finance.yahoo.comPrelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial ResultsNovember 1, 2023 | financialpost.comPrelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyOctober 19, 2023 | msn.comHC Wainwright & Co. Maintains Prelude Therapeutics (PRLD) Buy RecommendationOctober 19, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Prelude TherapeuticsOctober 19, 2023 | markets.businessinsider.comPotential Upside in Prelude Therapeutics: A Focused Analysis on PRT2527 and PRT3789 DevelopmentOctober 14, 2023 | markets.businessinsider.comPrelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International ConferenceOctober 14, 2023 | finance.yahoo.comPrelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International ConferenceOctober 6, 2023 | msn.comPrelude Therapeutics (PRLD) Price Target Increased by 11.70% to 10.71October 4, 2023 | finance.yahoo.comAll You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to BuyOctober 2, 2023 | benzinga.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the FirmSeptember 12, 2023 | marketbeat.comBoxer Capital LLC Acquires Shares of 699,047 Prelude Therapeutics Incorporated (NASDAQ:PRLD)Boxer Capital LLC bought a new stake in Prelude Therapeutics Incorporated (NASDAQ:PRLD - Free Report) in the 1st quarter, according to its most recent filing with the SEC. The fund bought 699,047 shares of the company's stock, valued at approximately $3,985,000. Boxer Capital LLC owned 1.46% of PreAugust 29, 2023 | finance.yahoo.comPrelude Therapeutics to Participate in Three Healthcare Investor Conferences in SeptemberAugust 29, 2023 | finance.yahoo.comPrelude Therapeutics to Participate in Three Healthcare Investor Conferences in SeptemberAugust 21, 2023 | marketbeat.comResearch Analysts Offer Predictions for Prelude Therapeutics Incorporated's Q3 2023 Earnings (NASDAQ:PRLD)Prelude Therapeutics Incorporated (NASDAQ:PRLD - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2023 earnings estimates for Prelude Therapeutics in a report issued on Thursday, August 17th. HC Wainwright analyst R. Burns anticipates that the company will earn ($0.56) p Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Millionaire Says: “Buy This $11 AI Coin.” (Ad)Right now, you can harness the power of two bull markets... Artificial intelligence...And cryptos. Find out more about this $11 AI Coin right now PRLD Media Mentions By Week PRLD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRLD News Sentiment▼0.570.57▲Average Medical News Sentiment PRLD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRLD Articles This Week▼91▲PRLD Articles Average Week Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Skye Bioscience News Incannex Healthcare News CervoMed News ProQR Therapeutics News I-Mab News InterCure News Regulus Therapeutics News Gossamer Bio News Seres Therapeutics News Adicet Bio News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRLD) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersGuard Against the Coming Financial UpheavalPorter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe only AI company you should be looking atBehind the MarketsCharles Payne Demystifies OptionsUnstoppable ProsperityForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
